It’s a global fight now, see for example this short report on an ‘access to medicines’ fight in Canada:
“Canadian pharmaceutical industry lobby groups, in an effort to head off a planned crackdown on prescription drug prices, offered to give up C$8.6 billion ($6.6 billion) in revenue over 10 years, freeze prices or reduce the cost of treating rare diseases, according to interviews and documents seen by Reuters….”
IP Watch – Current R&D Causes High Prices In Drugs; New Model Needed To Make Drugs More Affordable, Speakers Say
Short report of a side session at PMAC.
“The current research and development model may encourage innovation in medicines, but has caused drugs to become unaffordable and inaccessible for people, particularly those in low- and middle-income countries, panellists and participants at a major conference here said. Speakers at the meeting have suggested ideas and proposals in hope to make drugs more affordable and accessible for patients, with many talking about more involvement by the public sector in research and development. They were discussing at a side meeting of Prince Mahidol Award Conference (PMAC) 2019, which is an annual international conference focusing on policy-related health issues, as said on its website. A panel at the conference held on 30 January was entitled, “Research & development of NCD medicines: how can affordability be built into the business model?” The event was moderated by Suerie Moon of the Graduate Institute Global Health Centre in Geneva. Discussions focused on how R&D could continue to produce safe and efficacious drugs while making it more affordable and accessible….”